lung cancer

The privately held Cambridge, UK-based company announced earlier this month that it had raised an additional £11 million to support the commercialization of its platform.

The financing will be used by the company to bring its breath-based diagnostic technology to market, fund clinical trials, and grow its precision medicine services.

The company plans to launch an RNA sequencing-based test to help subtype and determine treatment for thyroid cancer, and a test to detect noninvasive lung cancer.

The companies will work together to develop a series of cancer screening tests that employ Preora's cytology platform and its sample-preparation technologies.

They acknowledge that while the technical hurdles of proteomic test development have become manageable, commercialization is still a major challenge.

The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.

The new guidelines said ROS1, KRAS, BRAF, MET, RET, and HER2 should be included in targeted and expanded panels.

Under the deal, Hong Kong-based Genostics will have the exclusive rights to manufacture and distribute EarlyCDT products in China.

One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.

The firm's blood-based Epi proLung lung cancer test looks for a combination of DNA methylation biomarkers.